<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">UR</journal-id><journal-title-group><journal-title>Urology Research</journal-title></journal-title-group><issn>3083-4910</issn><eissn>2981-8230</eissn><publisher><publisher-name>Bio-Byword Scientific Publishing Pty. Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26689/ur.v1i3.5986</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>Evaluation of the Effect of Transurethral Resection of Bladder Tumors in the Treatment of Bladder Cancer and its Impact on CA19-9 and CA125 Levels</title><url>https://artdesignp.com/journal/UR/1/3/10.26689/ur.v1i3.5986</url><author>WangPeigeng</author><pub-date pub-type="publication-year"><year>2023</year></pub-date><volume>1</volume><issue>3</issue><history><date date-type="pub"><published-time>2023-12-30</published-time></date></history><abstract>Objective: To evaluate the impact of transurethral resection of bladder tumors on surgical outcomes and serum tumor markers CA19-9 and CA125 in patients with bladder cancer. Methods: 80 patients with bladder cancer admitted to our hospital were selected and divided into two groups according to different treatment methods, with 40 cases in each group. The control group underwent open resection of bladder tumor, and the observation group adopted transurethral resection of bladder tumors. The two groups’ surgical indicators and levels of serum tumor markers CA19-9 and CA125 before and after treatment were observed and compared. Results: The operation time, bladder irrigation time, and intraoperative bleeding volume of the observation group were less than those of the control group, and the difference was statistically significant (P &amp;lt; 0.05); Before surgery, there was no statistically significant difference in serum CA19-9 and CA125 levels (P &amp;gt; 0.05). After surgery, the serum CA19-9 and CA125 levels of the two groups of patients were significantly lower than those before surgery. Moreover, the serum CA19-9 and CA125 levels in the observation group were significantly lower than those in the control group after surgery (P &amp;lt; 0.05). Conclusion: Transurethral resection of bladder tumors in the treatment of bladder cancer can significantly improve various surgical indicators and reduce the levels of bladder cancer tumor markers CA19-9 and CA125. The surgical effect and prognosis are good and it is worthy of clinical application and promotion.</abstract><keywords/></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>Yang Z, 2022, Effect of Transurethral Needle Electrode En-Bloc Resection of Bladder Tumors in the Treatment of Non-Muscle Invasive Bladder Cancer. Journal of Chronic Diseases, 23(12): 1895–1897 + 1901.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><p>Gao L, Sheng J, Tang P, et al., 2022, Influencing Factors of Recurrence in Patients with Non-Muscle Invasive Bladder Cancer After Transurethral Resection of Bladder Tumors. Journal of Practical Cancer, 37(11): 1886–1888.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><p>Tong X, Xiao J, Chen M, et al., 2022, Analysis of the Efficacy of Transurethral Needle Electrode Bladder Tumor Enucleation in Treating Non-Invasive Bladder Cancer. Modern Oncology, 30(24): 4518–4521.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><p>Zhang G, 2021, Study on the Expression and Diagnostic Efficacy of CEA, CA19-9, CA125, and AFP in Hemodialysis CKD Patients with Malignant Tumors. International Journal of Laboratory Medicine, 42(16): 1971–1976.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><p>Yang H, Ying M, Xia J, 2022, Clinical Effects of Transurethral Holmium Laser Bladder Tumor Resection and Transurethral Resection of Bladder Tumors in the Treatment of Patients with Superficial Bladder Cancer. Medical Equipment, 35(16): 47–50.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><p>Tian T, Wang G, Fang D, et al., 2022, Safety Analysis of Negative Pressure Suction Transurethral Bladder Tumor Resection in Treating Non-Muscle Invasive Bladder Cancer. Journal of Clinical Urology, 37(10): 783–786.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><p>Xie M, Sha W, Cui Q, et al., 2021, Preoperative Serum NLR, CA19-9, and IL-2 Levels Have Prognostic Evaluation Value in Patients with Invasive Bladder Cancer. Experimental and Laboratory Medicine, 39(3): 624–627 + 634.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><p>Yang J, 2022, Constructing a Risk Model for Bladder Cancer Recurrence Based on Urine CA19-9 and CEA. Medical Theory and Practice, 35(24): 4255–4258.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><p>Tao W, Xu M, Zhu J, et al., 2021, Comparison of the Efficacy of 980 nm Red Laser Transurethral Bladder Tumor En-Bloc Resection and Transurethral Resection of Bladder Tumors in Treating Non-Muscle Invasive Bladder Cancer. China Minimally Invasive Journal of Surgery, 21(12): 1086–1090.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><p>Wu H, Liu Y, Liu J, 2021, Clinical Effect of Transurethral Holmium Laser Resection of Bladder Tumors in the Treatment of Non-Muscle Invasive Bladder Cancer. Henan Journal of Surgery, 27(5): 68–70.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><p>Tang K, Cao G, Li X, et al., 2021, Comparison of Clinical Effects of Transurethral Holmium Laser Bladder Tumor Resection in Treating Non-Muscle Invasive Bladder Cancer. Jilin Medicine, 42(5): 1174–1175.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><p>Lin Y, 2021, Comparison of the Effects of Transurethral Bladder Tumor Enucleation and Bladder Tumor Resection in the Treatment of Non-Muscle Invasive Bladder Cancer. Fujian Medical Journal, 43(1): 102–105.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
